MedPath

Effect of E171 (titanium dioxide) in the colo

Conditions
E171, Titanium dioxide, Gut inflammation, BiomarkerE171, Titanium dioxide, Darm inflammatie, Biomarker
Registration Number
NL-OMON20868
Lead Sponsor
Maastricht University
Brief Summary

rrutia-Ortega, I.M., Garduño-Balderas L.G. , Freyre-Fonseca V., Delgado-Buenrostro N.L. , González-Robles A., Pedraza-Chaverri J., Hernandez-Pando R., Terrazas-Balderas L.I., van Loveren H., Chirino Y.I. (2016) E171 exposure exacerbates tumor formation in azoxymethane-induced colorectal cancer. Food and Chemical Toxicology.

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
80
Inclusion Criteria

Healthy with a Body Mass Index (BMI) between 18-27, male or female

- Between 18-70 years old

Exclusion Criteria

- Alcohol abuse up to 6 months before participation in this research, i.e. more than 4 drinks on any single day and more than 14 drinks per week for men and more than 3 drinks on any single day and more than 7 drinks per week for women
- Current presence of any diseases related to the gastrointestinal tract, kidney, liver, heart or lungs

- Current presence of symptoms related to diseases of the gastrointestinal tract, i.e. vomiting, diarrhoea or constipation, and altered stool, such as blood in stool

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary outcome parameters are differences in transcriptomic markers after consumption of food additive E171. These outcomes in humans will shed light on the relevance of markers identified in preclinical studies, and how the animal data on the risk of facilitation of tumour growth can be extrapolated to humans
Secondary Outcome Measures
NameTimeMethod
Secondary outcome parameters include inflammatory markers such as ROS in the rectal epithelium. These outcomes will help to understand the inflammatory mechanisms that may be indicative of the risk to developing colorectal cancer.
© Copyright 2025. All Rights Reserved by MedPath